{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:27Z","timestamp":1791295647317,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Previous small studies have reported familial clustering of myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). We identified 6217 PV, 2838 ET, 1172 MF, and 812 MPN unclassifiable (NOS) patients diagnosed in Sweden, 43\u2009550 controls, and first-degree relatives of cases (n = 24\u2009577) and controls (n = 99\u2009542). Using a marginal survival model, we calculated relative risks (RRs) and 95% confidence intervals as measures of familial aggregation. Relatives of MPN patients had significantly increased risks of PV (RR = 5.7; 3.5-9.1), ET (RR = 7.4; 3.7-14.8), and MPN NOS (RR = 7.5; 2.7-20.8). Analyses stratified by type of first-degree relative revealed consistently higher risks for siblings, compatible with a model of recessive genetic inheritance, which can be confirmed only by identifying the susceptibility gene(s). Mean age at MPN diagnosis was not different (P = .20) for affected relatives of cases (57.5 years) versus controls (60.6 years), and risk of MPN by age was not different for parents versus offspring of MPN cases (P = .10), providing no support for anticipation. Relatives of MPN patients had a borderline increased risk of chronic myeloid leukemia (CML; RR = 1.9; 0.9-3.8; P = .09). Our findings of 5- to 7-fold elevated risk of MPNs among first-degree relatives of MPN patients support the hypothesis that common, strong, shared susceptibility genes predispose to PV, ET, MF, and possibly CML.<\/jats:p>","DOI":"10.1182\/blood-2008-03-143602","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T01:35:12Z","timestamp":1209864912000},"page":"2199-2204","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":214,"title":["Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24\u2009577 first-degree relatives of 11\u2009039 patients with myeloproliferative neoplasms in Sweden"],"prefix":"10.1182","volume":"112","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, MD;"},{"name":"Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Goldin","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin A.","family":"Helgadottir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stockholm South Hospital, Stockholm, Sweden; and"},{"name":"Swedish Myeloproliferative Disorder Study Group, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden;"},{"name":"Swedish Myeloproliferative Disorder Study Group, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111714414169200_B1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"2019111714414169200_B2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders.","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"key":"2019111714414169200_B3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"2019111714414169200_B4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1600-0609.2008.01038.x","article-title":"20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.","volume":"80","author":"Tefferi","year":"2008","journal-title":"Eur J Haematol"},{"key":"2019111714414169200_B5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"2019111714414169200_B6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis.","volume":"2007","author":"Hoffman","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111714414169200_B7","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"2019111714414169200_B8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.","volume":"108","author":"Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"key":"2019111714414169200_B9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2005.05683.x","article-title":"The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.","volume":"130","author":"Cario","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111714414169200_B10","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2003-03-0885","article-title":"Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease.","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"2019111714414169200_B11","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1182\/blood-2005-12-4988","article-title":"Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.","volume":"107","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"2019111714414169200_B12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.22240","article-title":"JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.","volume":"107","author":"Rumi","year":"2006","journal-title":"Cancer"},{"key":"2019111714414169200_B13","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111714414169200_B14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.seminhematol.2005.08.002","article-title":"Lessons from familial myeloproliferative disorders.","volume":"42","author":"Skoda","year":"2005","journal-title":"Semin Hematol"},{"key":"2019111714414169200_B15","article-title":"Socialstyrelsen. Cancer incidence in Sweden 2001.","year":"2003"},{"key":"2019111714414169200_B16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","article-title":"Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964\u20132003.","volume":"121","author":"Turesson","year":"2007","journal-title":"Int J Cancer"},{"key":"2019111714414169200_B17","first-page":"339","article-title":"Diagnosis and classification of the polycythemias.","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin Haematol"},{"key":"2019111714414169200_B18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/10428199609074359","article-title":"Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis.","volume":"22","author":"Kutti","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2019111714414169200_B19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1600-0609.2005.00424.x","article-title":"Management of patients with polycythaemia vera: results of a survey among Swedish haematologists.","volume":"74","author":"Andreasson","year":"2005","journal-title":"Eur J Haematol"},{"key":"2019111714414169200_B20","article-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Jaffe","year":"2001"},{"key":"2019111714414169200_B21","article-title":"Flergenerationsregistret: Statistics Sweden.","author":"Skarle","year":"2001"},{"key":"2019111714414169200_B22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gepi.1370080505","article-title":"Estimating effects of probands' characteristics on familial risk: I. Adjustment for censoring and correlated ages at onset.","volume":"8","author":"Liang","year":"1991","journal-title":"Genet Epidemiol"},{"key":"2019111714414169200_B23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1046\/j.1529-8817.2003.00111.x","article-title":"Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data.","volume":"68","author":"Pfeiffer","year":"2004","journal-title":"Ann Hum Genet"},{"key":"2019111714414169200_B24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia.","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"2019111714414169200_B25","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/6\/2199\/1482493\/zh801808002199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/6\/2199\/1482493\/zh801808002199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T14:41:51Z","timestamp":1574001711000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/6\/2199\/24812\/Increased-risks-of-polycythemia-vera-essential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,15]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-03-143602","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1115124.571107","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,15]]}}}